Literature DB >> 22550168

BEAMing up personalized medicine: mutation detection in blood.

Andrea L Richardson1, J Dirk Iglehart.   

Abstract

BEAMing is a feasible, accurate, and sensitive method for detection of PIK3CA mutations in circulating tumor DNA in blood. Mutation status of PIK3CA may change between primary tumor and recurrence. The results suggest a new approach for noninvasive determination of current mutation status in patients with metastatic disease. ©2012 AACR.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22550168      PMCID： PMC3377838          DOI： 10.1158/1078-0432.CCR-12-0871

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions.

Authors:  Frank Diehl; Meng Li; Yiping He; Kenneth W Kinzler; Bert Vogelstein; Devin Dressman
Journal:  Nat Methods       Date:  2006-07       Impact factor: 28.547

2.  A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

Authors:  Zengliu Su; Dora Dias-Santagata; Markeesa Duke; Katherine Hutchinson; Ya-Lun Lin; Darrell R Borger; Christine H Chung; Pierre P Massion; Cindy L Vnencak-Jones; A John Iafrate; William Pao
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

3.  Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.

Authors:  Michaela J Higgins; Danijela Jelovac; Evan Barnathan; Brian Blair; Shannon Slater; Penny Powers; Jane Zorzi; Stacie C Jeter; George R Oliver; John Fetting; Leisha Emens; Carol Riley; Vered Stearns; Frank Diehl; Philipp Angenendt; Peng Huang; Leslie Cope; Pedram Argani; Kathleen M Murphy; Kurtis E Bachman; Joel Greshock; Antonio C Wolff; Ben H Park
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

4.  Detection and quantification of mutations in the plasma of patients with colorectal tumors.

Authors:  Frank Diehl; Meng Li; Devin Dressman; Yiping He; Dong Shen; Steve Szabo; Luis A Diaz; Steven N Goodman; Kerstin A David; Hartmut Juhl; Kenneth W Kinzler; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-28       Impact factor: 11.205

5.  Clinical trials in the era of personalized oncology.

Authors:  Michael L Maitland; Richard L Schilsky
Journal:  CA Cancer J Clin       Date:  2011-10-27       Impact factor: 508.702

6.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Authors:  Katherine Stemke-Hale; Ana Maria Gonzalez-Angulo; Ana Lluch; Richard M Neve; Wen-Lin Kuo; Michael Davies; Mark Carey; Zhi Hu; Yinghui Guan; Aysegul Sahin; W Fraser Symmans; Lajos Pusztai; Laura K Nolden; Hugo Horlings; Katrien Berns; Mien-Chie Hung; Marc J van de Vijver; Vicente Valero; Joe W Gray; René Bernards; Gordon B Mills; Bryan T Hennessy
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Circulating mutant DNA to assess tumor dynamics.

Authors:  Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Nat Med       Date:  2007-07-31       Impact factor: 53.440

8.  Genome remodelling in a basal-like breast cancer metastasis and xenograft.

Authors:  Li Ding; Matthew J Ellis; Shunqiang Li; David E Larson; Ken Chen; John W Wallis; Christopher C Harris; Michael D McLellan; Robert S Fulton; Lucinda L Fulton; Rachel M Abbott; Jeremy Hoog; David J Dooling; Daniel C Koboldt; Heather Schmidt; Joelle Kalicki; Qunyuan Zhang; Lei Chen; Ling Lin; Michael C Wendl; Joshua F McMichael; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Elizabeth Appelbaum; Katherine Deschryver; Sherri Davies; Therese Guintoli; Li Lin; Robert Crowder; Yu Tao; Jacqueline E Snider; Scott M Smith; Adam F Dukes; Gabriel E Sanderson; Craig S Pohl; Kim D Delehaunty; Catrina C Fronick; Kimberley A Pape; Jerry S Reed; Jody S Robinson; Jennifer S Hodges; William Schierding; Nathan D Dees; Dong Shen; Devin P Locke; Madeline E Wiechert; James M Eldred; Josh B Peck; Benjamin J Oberkfell; Justin T Lolofie; Feiyu Du; Amy E Hawkins; Michelle D O'Laughlin; Kelly E Bernard; Mark Cunningham; Glendoria Elliott; Mark D Mason; Dominic M Thompson; Jennifer L Ivanovich; Paul J Goodfellow; Charles M Perou; George M Weinstock; Rebecca Aft; Mark Watson; Timothy J Ley; Richard K Wilson; Elaine R Mardis
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

9.  Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Authors:  José Baselga; Vladimir Semiglazov; Peter van Dam; Alexey Manikhas; Meritxell Bellet; José Mayordomo; Mario Campone; Ernst Kubista; Richard Greil; Giulia Bianchi; Jutta Steinseifer; Betty Molloy; Erika Tokaji; Humphrey Gardner; Penny Phillips; Michael Stumm; Heidi A Lane; J Michael Dixon; Walter Jonat; Hope S Rugo
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

10.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245
View more
  17 in total

1.  Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.

Authors:  F Xie; P Li; J Gong; H Tan; J Ma
Journal:  Clin Transl Oncol       Date:  2017-09-27       Impact factor: 3.405

Review 2.  Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.

Authors:  Chien-Chung Lin; Wei-Lun Huang; Fang Wei; Wu-Chou Su; David T Wong
Journal:  Expert Rev Mol Diagn       Date:  2015-09-30       Impact factor: 5.225

3.  Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.

Authors:  Lillian M Smyth; Kenji Tamura; Mafalda Oliveira; Eva M Ciruelos; Ingrid A Mayer; Marie-Paule Sablin; Laura Biganzoli; Helen J Ambrose; Jack Ashton; Alan Barnicle; Des D Cashell; Claire Corcoran; Elza C de Bruin; Andrew Foxley; Joana Hauser; Justin P O Lindemann; Rhiannon Maudsley; Robert McEwen; Michele Moschetta; Martin Pass; Vicky Rowlands; Gaia Schiavon; Udai Banerji; Maurizio Scaltriti; Barry S Taylor; Sarat Chandarlapaty; José Baselga; David M Hyman
Journal:  Clin Cancer Res       Date:  2020-04-20       Impact factor: 12.531

Review 4.  Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.

Authors:  Virginia G Kaklamani; Andrea L Richardson; Carlos L Arteaga
Journal:  Oncologist       Date:  2019-01-16

5.  Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor.

Authors:  Guhyun Kang; Byeong Seok Sohn; Jung-Soo Pyo; Jung Yeon Kim; Boram Lee; Kyoung-Mee Kim
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

6.  Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.

Authors:  Guhyun Kang; Byung Noe Bae; Byeong Seok Sohn; Jung-Soo Pyo; Gu Hyum Kang; Kyoung-Mee Kim
Journal:  Target Oncol       Date:  2015-03-05       Impact factor: 4.493

7.  Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.

Authors:  S Chen; J Zhao; L Cui; Y Liu
Journal:  Clin Transl Oncol       Date:  2016-07-28       Impact factor: 3.405

Review 8.  Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB).

Authors:  Michael Tu; David Chia; Fang Wei; David Wong
Journal:  Analyst       Date:  2016-01-21       Impact factor: 4.616

9.  Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.

Authors:  Christina M Wood-Bouwens; Derrick Haslem; Bryce Moulton; Alison F Almeda; Hojoon Lee; Gregory M Heestand; Lincoln D Nadauld; Hanlee P Ji
Journal:  J Mol Diagn       Date:  2019-12-16       Impact factor: 5.568

10.  Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.

Authors:  D E Rathkopf; M R Smith; C J Ryan; W R Berry; N D Shore; G Liu; C S Higano; J J Alumkal; R Hauke; R F Tutrone; M Saleh; E Chow Maneval; S Thomas; D S Ricci; M K Yu; C J de Boer; A Trinh; T Kheoh; R Bandekar; H I Scher; E S Antonarakis
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.